Curcumin, the golden spice in treating cardiovascular diseases.

Cardiovascular diseases Clinical trials Curcumin Molecular targets Nutraceuticals

Journal

Biotechnology advances
ISSN: 1873-1899
Titre abrégé: Biotechnol Adv
Pays: England
ID NLM: 8403708

Informations de publication

Date de publication:
Historique:
received: 28 08 2018
revised: 10 01 2019
accepted: 29 01 2019
pubmed: 5 2 2019
medline: 27 2 2020
entrez: 5 2 2019
Statut: ppublish

Résumé

Cardiovascular diseases (CVDs) cause the largest mortality worldwide, and much attention has been focused to unravel the mechanisms and optimize the treatment regimens. Curcumin is an important bioactive component of turmeric that has been widely applied as traditional medicine to prevent and treat various diseases in some countries. Recent studies have demonstrated its potent activities in modulating multiple signaling pathways associated with cellular growth, proliferation, survival, inflammation and oxidative stress. The cardiovascular protective properties of curcumin in CVDs have been fully illustrated in numerous studies. In this review, we first briefly introduce the medicinal history of curcumin. Secondly, we systematically analyze the preclinical studies of curcumin in CVDs such as cardiac hypertrophy, heart failure, drug-induced cardiotoxicity, myocardial infarction, atherosclerosis, abdominal aortic aneurysm, stroke and diabetic cardiovascular complications. The potential molecular targets of curcumin are also summarized. Thirdly, the clinical trials of curcumin in CVDs are overviewed and discussed. Finally, we discuss the therapeutic utility of derivatives of curcumin, and highlight existing problems of curcumin as an effective drug lead in treating CVDs.

Identifiants

pubmed: 30716389
pii: S0734-9750(19)30010-2
doi: 10.1016/j.biotechadv.2019.01.010
pii:
doi:

Substances chimiques

Curcumin IT942ZTH98

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

107343

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Hong Li (H)

Department of Biochemistry and Molecular Biology, Guangzhou University of Chinese Medicine, Guangzhou 510006, Guangdong, China; The Research Center of Basic Integrative Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510006, Guangdong, China.

Antoni Sureda (A)

Research Group on Community Nutrition and Oxidative Stress, University of the Balearic Islands, Palma de Mallorca, Spain and CIBEROBN (Physiopathology of Obesity and Nutrition CB12/03/30038), Instituto de Salud Carlos III, Madrid, Spain.

Hari Prasad Devkota (HP)

School of Pharmacy, Kumamoto University, 5-1 Oe-honmachi, Chuo ku, Kumamoto 862-0973, Japan.

Valeria Pittalà (V)

Department of Drug Sciences, University of Catania, Viale Andrea Doria 6, 95125 Catania, Italy.

Davide Barreca (D)

Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale F. Stagno d'Alcontres 31, 98166 Messina, Italy.

Ana Sanches Silva (AS)

National Institute of Agrarian and Veterinary Research (INIAV), Rua dos Lágidos, Lugar da Madalena, Vairão, Vila do Conde, Oporto 4485-655, Portugal; Center for Study in Animal Science (CECA), ICETA, University of Oporto, Oporto, Portugal.

Devesh Tewari (D)

Department of Pharmaceutical Sciences, Faculty of Technology, Bhimtal Campus, Kumaun University, Nainital, Uttarakhand, India.

Suowen Xu (S)

Aab Cardiovascular Research Institute, University of Rochester, Rochester, NY 14623, USA. Electronic address: Suowen_Xu@URMC.Rochester.edu.

Seyed Mohammad Nabavi (SM)

Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran 14359-16471, Iran. Electronic address: Nabavi208@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH